Xiaomai Wu

410 total citations
11 papers, 62 citations indexed

About

Xiaomai Wu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Infectious Diseases. According to data from OpenAlex, Xiaomai Wu has authored 11 papers receiving a total of 62 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 2 papers in Infectious Diseases. Recurrent topics in Xiaomai Wu's work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (2 papers). Xiaomai Wu is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (2 papers). Xiaomai Wu collaborates with scholars based in China and United States. Xiaomai Wu's co-authors include Dongqing Lv, Zhengqing Yan, Guoqiang Wang, Minfei Peng, Jian Lin, Yi Deng, Sen Yang, Yaping Wang, Weineng Feng and Ling Lin and has published in prestigious journals such as Medicine, Journal of Thoracic Oncology and OncoTargets and Therapy.

In The Last Decade

Xiaomai Wu

9 papers receiving 61 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaomai Wu China 5 50 25 17 6 6 11 62
Clementine Bostantzoglou Greece 4 38 0.8× 31 1.2× 4 0.2× 7 1.2× 4 0.7× 12 60
Raminder Aul United Kingdom 3 41 0.8× 29 1.2× 13 0.8× 10 1.7× 1 0.2× 9 67
Hiram Rivas-Perez United States 4 53 1.1× 8 0.3× 25 1.5× 12 2.0× 1 0.2× 5 78
A.J. James United Kingdom 3 51 1.0× 48 1.9× 3 0.2× 13 2.2× 3 0.5× 3 81
Heidi Schaarschmidt Germany 2 29 0.6× 30 1.2× 8 0.5× 9 1.5× 2 46
Corinna Slawinski United Kingdom 2 9 0.2× 16 0.6× 29 1.7× 10 1.7× 7 1.2× 4 45
Teresa Panzera Italy 6 8 0.2× 13 0.5× 12 0.7× 7 1.2× 7 1.2× 16 64
Marc Giovaninni France 4 35 0.7× 31 1.2× 13 0.8× 9 1.5× 7 59
Takehiko Ohba Japan 4 35 0.7× 6 0.2× 8 0.5× 10 1.7× 1 0.2× 6 43
Jessica Tantivit United States 2 18 0.4× 33 1.3× 5 0.3× 7 1.2× 1 0.2× 3 67

Countries citing papers authored by Xiaomai Wu

Since Specialization
Citations

This map shows the geographic impact of Xiaomai Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaomai Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaomai Wu more than expected).

Fields of papers citing papers by Xiaomai Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaomai Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaomai Wu. The network helps show where Xiaomai Wu may publish in the future.

Co-authorship network of co-authors of Xiaomai Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaomai Wu. A scholar is included among the top collaborators of Xiaomai Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaomai Wu. Xiaomai Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
2.
Chen, Shuaishuai, Mengyuan Chen, Tongtong Zhang, et al.. (2023). Assessment of the Risk and Symptoms of SARS-CoV-2 Infection Among Healthcare Workers During the Omicron Transmission Period: A Multicentric Study from Four Hospitals of Mainland China. Infection and Drug Resistance. Volume 16. 3315–3328. 3 indexed citations
3.
Lin, Jian, Xiaomai Wu, & Minfei Peng. (2021). Nocardia cyriacigeorgica infection in a patient with pulmonary sequestration: A case report. World Journal of Clinical Cases. 9(10). 2367–2372. 4 indexed citations
4.
Gu, Qianqian, Shuangquan Yan, Xiaomai Wu, et al.. (2021). Choriocarcinoma Masquerading as Lung Abscess or Lung Cancer: A Case with Atypical Imaging Findings. OncoTargets and Therapy. Volume 14. 4407–4414.
6.
Lin, Ling, et al.. (2020). <p>Response to Afatinib in a Patient with NSCLC Harboring Novel <em>EGFR</em> Exon 20 Insertion Mutations</p>. OncoTargets and Therapy. Volume 13. 9753–9757. 8 indexed citations
7.
Deng, Yi, Ying Tang, Sen Yang, et al.. (2020). Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.. PubMed. 24(14). 7664–7672. 10 indexed citations
8.
Lin, Ling, et al.. (2019). <p>Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report</p>. OncoTargets and Therapy. Volume 12. 10897–10902. 3 indexed citations
9.
Wu, Xiaomai, et al.. (2018). P1.15-32 Real World EGFR Mutation Profile from 1699 Non-Small Cell Lung Cancer Patients in Eastern China. Journal of Thoracic Oncology. 13(10). S625–S626. 1 indexed citations
10.
Yang, Haihua, et al.. (2018). P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC. Journal of Thoracic Oncology. 13(10). S807–S807. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026